Tìm theo
Ketoprofen
Các tên gọi khác (8 ) :
  • 2-(3-Benzoylphenyl)propionic acid
  • 3-Benzoyl-alpha-methylbenzeneacetic acid
  • 3-Benzoyl-α-methylbenzeneacetic acid
  • 3-Benzoylhydratropic acid
  • Ketoprofen
  • L'Acide (benzoyl-3-phenyl)-2-propionique
  • m-Benzoylhydratropic acid
  • Orudis (tn)
Thuốc giảm đau, hạ sốt, chống viêm không steroid, điều trị Gút và các bệnh xương khớp
Thuốc Gốc
Small Molecule
CAS: 22071-15-4
ATC: M01AE03, M01AE17, M02AA10
ĐG : Aidarex Pharmacuticals LLC , http://www.aidarex.com
CTHH: C16H14O3
PTK: 254.2806
Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C16H14O3
Phân tử khối
254.2806
Monoisotopic mass
254.094294314
InChI
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChI Key
InChIKey=DKYWVDODHFEZIM-UHFFFAOYSA-N
IUPAC Name
2-(3-benzoylphenyl)propanoic acid
Traditional IUPAC Name
ketoprofen
SMILES
CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Độ tan chảy
94 °C
Độ hòa tan
51 mg/L (at 22 °C)
logP
3.12
logS
-3.7
pKa (strongest acidic)
3.88
pKa (Strongest Basic)
-7.5
PSA
54.37 Å2
Refractivity
72.52 m3·mol-1
Polarizability
26.56 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
-1
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
pKa
4.45
Dược Lực Học : Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Cơ Chế Tác Dụng : Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Dược Động Học :
▧ Absorption :
Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
▧ Protein binding :
99% bound, primarily to albumin
▧ Metabolism :
Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
▧ Route of Elimination :
In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
▧ Half Life :
Conventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)


▧ Clearance :
* Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)] * Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)] * 0.08 L/kg/h * 0.7 L/kg/h [alcoholic cirrhosis patients]
Độc Tính : LD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.

Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.
Chỉ Định : For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Tương Tác Thuốc :
  • Acenocoumarol The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol.
  • Acetylsalicylic acid Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.
  • Anisindione The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione.
  • Azilsartan medoxomil Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
  • Citalopram Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Colesevelam Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
  • Cyclosporine The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine.
  • Dicoumarol The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol.
  • Drotrecogin alfa The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
  • Eltrombopag Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
  • Escitalopram Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Fluoxetine Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Fluvoxamine Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Ginkgo biloba Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
  • Ginseng Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
  • Ketorolac Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).
  • Lithium The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed.
  • Methotrexate The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
  • Paroxetine Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Pemetrexed The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy.
  • S-Adenosylmethionine Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
  • Sertraline Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy.
  • Telmisartan Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
  • Timolol The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol.
  • Trandolapril The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.
  • Treprostinil The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy.
  • Warfarin The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Liều Lượng & Cách Dùng : Capsule - Oral - 100 mg
Capsule - Oral - 50 mg
Capsule - Oral - 75 mg
Capsule, extended release - Oral - 200 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Actron
  • Công ty : Teofarma
    Sản phẩm biệt dược : Alrheumun
  • Công ty : Kissei
    Sản phẩm biệt dược : Capisten
  • Công ty : Zeria Shinyaku
    Sản phẩm biệt dược : Epatec
  • Công ty : Menarini
    Sản phẩm biệt dược : Fastum
  • Công ty : Daiko Seiyaku
    Sản phẩm biệt dược : Menamin
  • Công ty : Abbott
    Sản phẩm biệt dược : Orudis
  • Công ty : Sanofi
    Sản phẩm biệt dược : Orudis KT
  • Công ty : Sanofi
    Sản phẩm biệt dược : Orugesic
  • Công ty : Wyeth
    Sản phẩm biệt dược : Oruvail
  • Công ty : Sanofi
    Sản phẩm biệt dược : Oscorel
  • Công ty : Sanofi
    Sản phẩm biệt dược : Profenid
  • Công ty : Sanofi
    Sản phẩm biệt dược : Toprec
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01009
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=3825
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505715
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C01716
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00132
ChemSpider
http://www.chemspider.com/Chemical-Structure.3693.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0378-4070-01
PharmGKB
http://www.pharmgkb.org/drug/PA450149
Wikipedia
http://en.wikipedia.org/wiki/Ketoprofen
RxList
http://www.rxlist.com/cgi/generic/ketoprof.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/oru1313.shtml
Drugs.com
http://www.drugs.com/cdi/ketoprofen.html